NO20074594L - 39-Desmetoksy-derivater av rapamycin - Google Patents

39-Desmetoksy-derivater av rapamycin

Info

Publication number
NO20074594L
NO20074594L NO20074594A NO20074594A NO20074594L NO 20074594 L NO20074594 L NO 20074594L NO 20074594 A NO20074594 A NO 20074594A NO 20074594 A NO20074594 A NO 20074594A NO 20074594 L NO20074594 L NO 20074594L
Authority
NO
Norway
Prior art keywords
diseases
rapamycin
treatment
desmethoxy
derivatives
Prior art date
Application number
NO20074594A
Other languages
English (en)
Norwegian (no)
Inventor
Christoph Hendrik Beckmann
Steven James Moss
Rose Mary Sheridan
Mingqiang Zhang
Barrie Wilkinson
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of NO20074594L publication Critical patent/NO20074594L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20074594A 2005-03-11 2007-09-11 39-Desmetoksy-derivater av rapamycin NO20074594L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504994.5A GB0504994D0 (en) 2005-03-11 2005-03-11 Novel compounds
PCT/GB2006/000853 WO2006095185A1 (en) 2005-03-11 2006-03-10 39-desmethoxy derivatives of rapamycin

Publications (1)

Publication Number Publication Date
NO20074594L true NO20074594L (no) 2007-10-15

Family

ID=34508873

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074594A NO20074594L (no) 2005-03-11 2007-09-11 39-Desmetoksy-derivater av rapamycin

Country Status (24)

Country Link
US (2) US7648996B2 (es)
EP (1) EP1856129B8 (es)
JP (1) JP5422788B2 (es)
KR (1) KR20070113282A (es)
CN (2) CN101175760B (es)
AU (1) AU2006221786B2 (es)
BR (1) BRPI0607441A2 (es)
CA (1) CA2600640C (es)
CR (1) CR9434A (es)
DK (1) DK1856129T3 (es)
ES (1) ES2527530T3 (es)
GB (1) GB0504994D0 (es)
HR (1) HRP20150012T1 (es)
IL (1) IL185688A0 (es)
MX (1) MX2007011131A (es)
NI (1) NI200700230A (es)
NO (1) NO20074594L (es)
NZ (1) NZ561607A (es)
PL (1) PL1856129T3 (es)
PT (1) PT1856129E (es)
RS (1) RS53778B1 (es)
RU (1) RU2391346C2 (es)
WO (1) WO2006095185A1 (es)
ZA (1) ZA200708601B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862538B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
NZ561647A (en) * 2005-03-11 2011-01-28 Biotica Tech Ltd Medical uses of 39-desmethoxyrapamycin and analogues thereof
WO2006095173A2 (en) * 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
GB0609963D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
MX2009010683A (es) * 2007-04-05 2010-01-20 Wyeth Corp Conjugado de wortmanina-rapamicina y usos del mismo.
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US8754207B2 (en) 2009-09-25 2014-06-17 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
CN106153755B (zh) * 2015-04-24 2020-02-14 山东新时代药业有限公司 2-(叔丁基二甲基硅烷基氧基)乙醇的分析检测方法
EP3341381A4 (en) * 2015-08-28 2019-06-12 Buck Institute for Research on Aging RAPAMYCIN ANALOGUE WITH IMPROVED MTORC1 SPECIFICITY
JP2020507632A (ja) * 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
AR112834A1 (es) * 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
EP3880266B1 (en) 2018-11-14 2025-05-07 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
WO2020163594A1 (en) 2019-02-07 2020-08-13 The Regents Of The University Of California Immunophilin binding agents and uses thereof
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
CA2102116A1 (en) 1991-05-31 1992-12-01 Gary R. Schulte Use of rapamycin prodrugs as immunosuppressant agents
US5708002A (en) 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9315914D0 (en) 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5995457A (en) * 1993-12-22 1999-11-30 Jamail; Randall H. Method of masking data on digital video disks (DVD)
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
PT956034E (pt) 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6485514B1 (en) 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
CA2377918A1 (en) 1999-07-09 2001-01-18 Bruce G. Gold Compositions and methods for promoting nerve regeneration
ATE527271T1 (de) 2000-04-27 2011-10-15 Univ Arizona Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
MX368013B (es) 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
CA2492153C (en) * 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound

Also Published As

Publication number Publication date
CA2600640A1 (en) 2006-09-14
US20100081682A1 (en) 2010-04-01
PT1856129E (pt) 2015-01-16
BRPI0607441A2 (pt) 2010-04-06
EP1856129B8 (en) 2015-06-03
ZA200708601B (en) 2009-02-25
MX2007011131A (es) 2007-11-13
US20080188511A1 (en) 2008-08-07
CA2600640C (en) 2015-10-27
US7648996B2 (en) 2010-01-19
AU2006221786B2 (en) 2012-02-16
EP1856129B1 (en) 2014-10-15
WO2006095185A1 (en) 2006-09-14
PL1856129T3 (pl) 2015-08-31
US8008318B2 (en) 2011-08-30
AU2006221786A1 (en) 2006-09-14
KR20070113282A (ko) 2007-11-28
RU2007137668A (ru) 2009-04-20
RU2391346C2 (ru) 2010-06-10
GB0504994D0 (en) 2005-04-20
IL185688A0 (en) 2008-01-06
RS53778B1 (sr) 2015-06-30
CR9434A (es) 2008-02-22
CN101175760B (zh) 2014-08-13
CN101175760A (zh) 2008-05-07
HRP20150012T1 (xx) 2015-03-27
NZ561607A (en) 2011-01-28
JP5422788B2 (ja) 2014-02-19
ES2527530T3 (es) 2015-01-26
NI200700230A (es) 2008-05-13
EP1856129A1 (en) 2007-11-21
JP2008532991A (ja) 2008-08-21
CN104211715A (zh) 2014-12-17
DK1856129T3 (en) 2015-01-05

Similar Documents

Publication Publication Date Title
NO20074594L (no) 39-Desmetoksy-derivater av rapamycin
IL278951A (en) History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of IKZF2-dependent diseases
ATE448232T1 (de) Substituierte heterozyklen
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
ECSP104578A (es) Derivados de indolilmaleimida como inhibidores de proteína de cinasa c
HK1203489A1 (en) Purinone compounds as kinase inhibitors
IL180979A0 (en) Isoindoline compounds and methods of making and using the same
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
IL288872B1 (en) IMIDAZO[1,5-c]PYRIMIDIN-5-AMINE PERI-CONDENSED DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USES IN CANCER TREATMENT
IL289164A (en) The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
FR2933979B1 (fr) Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
EA201892518A1 (ru) ЗАМЕЩЕННЫЕ 5,6,7,8-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИН-3(2H)-ОН И 2,5,6,7-ТЕТРАГИДРО-3H-ПИРРОЛО[2,1-c][1,2,4]ТРИАЗОЛ-3-ОН И ИХ ПРИМЕНЕНИЕ
EP4003355A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
EP4219458A3 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
EP3790866A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
EP4003987A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
WO2002013866A3 (en) Stimulating neutrophil function to treat inflammatory bowel disease
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
WO2021097434A8 (en) Fibroblast therapy for inflammatory bowel disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application